The use of beta-N-acetylglucosaminidase excretion to investigate renal disease in rheumatoid arthritis.
Urine levels of the lysosomal enzyme beta-N-acetylglucosaminidase have been measured in patients with arthritic disorders; significantly higher levels were found in patients with rheumatoid arthritis (mean: 332.9 nmol/h/mg creat.) than in those with degenerative joint disease (mean: 86.31 nmol/h/mg creat.; P less than 0.001). Analysis of the results shows that salicylates were responsible for some of this difference, but suggests that rheumatoid disease itself may cause renal damage.
D000118:Acetylglucosaminidase / Q000652:urine*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000652:urine*; D006596:Hexosaminidases / Q000652:urine*; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology*; D012459:Salicylates / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D012459:Salicylates; D006596:Hexosaminidases; D000118:Acetylglucosaminidase